Last quarter (Q3 2023), Cara Therapeutics's total revenue was $4.87M, a decrease of -55.00% from the same quarter last year. In Q3, Cara Therapeutics's net income was $-28.03M. See Cara Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	$ 19.70M	$ 41.87M	$ 23.03M	$ 135.08M	$ 19.89M	$ 13.47M
Cost of Revenue	$ -34.00K	$ -7.27M	-	-	-	-
Gross Profit	$ 21.23M	$ 34.60M	$ 23.03M	-	-	-
Operating Expense	$ 72.28M	$ -122.14M	$ -112.11M	$ 129.70M	$ 131.56M	$ 90.85M
Operating Income	$ -117.36M	$ -87.53M	$ -89.08M	$ 5.38M	$ -111.68M	$ -77.38M
Net Non Operating Interest Income Expense	-	-	-	-	-	-
Other Income Expense	$ -3.68M	$ -2.06M	$ -642.00K	$ 2.33M	$ 4.49M	$ 2.98M
Pretax Income	$ -110.56M	$ -85.47M	$ -88.44M	$ 7.72M	$ -107.19M	$ -74.40M
Tax Provision	-	-	-	$ -691.00K	$ -816.00K	$ -389.00K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -116.52M	$ -85.47M	$ -88.44M	$ 8.41M	$ -106.37M	$ -74.01M
Basic EPS	$ -2.15	$ -1.59	$ -1.74	$ 0.18	$ -2.49	$ -2.06
Diluted EPS	$ -2.15	$ -1.59	$ -1.74	$ 0.18	$ -2.49	$ -2.06
Basic Average Shares	$ 215.76M	$ 53.65M	$ 50.72M	$ 47.41M	$ 42.67M	$ 35.89M
Diluted Average Shares	$ 215.76M	$ 53.65M	$ 50.72M	$ 47.92M	$ 42.67M	$ 35.89M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 72.25M	$ 129.44M	$ -112.11M	$ 129.70M	$ 131.56M	$ 90.85M
Net Income From Continuing And Discontinued Operation	$ -116.52M	$ -85.47M	$ -88.44M	$ 8.41M	$ -106.37M	$ -74.01M
Normalized Income	$ -42.31M	$ -67.52M	-	$ 8.41M	$ -106.37M	$ -74.01M
Interest Expense	-	-	-	-	-	-
EBIT	$ -110.56M	$ -85.47M	$ -88.44M	$ 5.38M	$ -111.68M	$ -77.38M
EBITDA	$ -109.13M	$ -83.54M	$ -86.03M	$ 5.59M	$ -111.48M	$ -77.01M

Currency in USD

Cara Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing